Skip to Content
Aug 09 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Aug. 9, 2022-- Regulatory News : Nanobiotix (Paris:NANO) (NASDAQ:NBTX): Market: Euronext
Jul 08 2022
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS --(BUSINESS WIRE)--Jul. 8, 2022-- Regulatory News : Nanobiotix (Paris:NANO)(NASDAQ:NBTX) Market: Euronext Paris
May 18 2022
On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for
May 11 2022
PARIS & CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 11, 2022-- Regulatory News : NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the " Company "), a clinical-stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced that